Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19

Liaquat University of Medical & Health Sciences152 enrolled

Overview

The purpose of this study is to investigate if Quercetin Phytosome is beneficial for the treatment of COVID-19.

This is a randomized, open-labelled and controlled study aimed to investigate the adjuvant benefits of Quercetin Phytosome in community-based subjects with confirmed SARS-CoV-2 infection (by RT-PCR). The study has two arms. In one arm the subjects will receive standard COVID-19 care as per the hospital/physician guidelines, whereas in the other arm the subjects will receive standard COVID-19 care + Quercetin Phytosome. The treatment will continue for 30 days. It is proposed that Quercetin Phytosome will contribute to boosting the natural immunity of the subjects and will help in preventing the COVID-19 disease progression i.e preventing the need of hospitalisation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

152

Conditions

COVID-19

Interventions

Standard COVID-19 careDRUG

Patients will receive standard covid-19 care as per the hospital/physician guidelines

Quercetin PhytosomeDIETARY_SUPPLEMENT

Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years of either gender * Confirmed SARS-CoV-2 infection by RT-PCR * Currently diagnosed with mild-to-moderate symptoms of COVID-19 at home in self-isolation within 3 days of SARS-CoV-2 infection. * Displaying typical symptoms of COVID-19 such as a high temperature, a new, continuous cough, a loss or change to sense of smell or taste * Patients who have signed informed consent. Exclusion Criteria: * Patients with proven hypersensitivity or allergic reaction to quercetin * Manifest contrary will

Locations (1)

Liaquat University Hospital

Jāmshoro, Sindh, Pakistan

Outcomes

Primary Outcomes

Percentage of subjects with COVID-19 disease progression

Percentage of subjects who require hospitalisation

Time frame: From day 1 to day 30

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.